1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Phosphodiesterase (PDE)

Phosphodiesterase (PDE)

Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond. Usually, people speaking of phosphodiesterase are referring to cyclic nucleotide phosphodiesterases, which have great clinical significance and are described below. However, there are many other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. PDEs are therefore important regulators ofsignal transduction mediated by these second messenger molecules.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-90009D
    (6S,12aR)-Tadalafil
    Inhibitor 99.34%
    (6S,12aR)-Tadalafil (Tadalafil EP Impurity C) is a highly potent PDE5 inhibitor with an IC50 value of 5 nM and has blood pressure lowering activity.
    (6S,12aR)-Tadalafil
  • HY-141831
    STF-1084
    Inhibitor 99.40%
    STF-1084 is a specific, cell-impermeable, competitive inhibitor of ENPP1 (Ki = 33 nM). STF-1084 increases extracellular cGAMP concentrations by preventing its degradation by ENPP1, thereby enhancing immune infiltration. STF-1084 acts synergistically with ionizing radiation (IR) and cGAMP to delay tumor progression. STF-1084 can be used to study cancers with low immunogenicity.
    STF-1084
  • HY-163285
    PDE3B-IN-1
    Inhibitor
    PDE3B-IN-1 is a selective inhibitor for phosphodiesterase PDE3B with an IMAP pIC50 of 6.5 and a PDE3B/A selective index >300.
    PDE3B-IN-1
  • HY-100118
    BW-A 78U
    Inhibitor 99.67%
    BW-A 78U is a PDE4 inhibitor with an IC50 of 3 μM.
    BW-A 78U
  • HY-115871
    PDE4-IN-4
    Inhibitor
    PDE4-IN-4 is a dual M3 (pIC50 = 10.2) antagonist-PDE4 (pIC50 = 8.8) inhibitor for the inhaled research of pulmonary diseases.
    PDE4-IN-4
  • HY-106477
    Quazinone
    Inhibitor 99.7%
    Quazinone is a selective inhibitor of cGMP-inhibited-phosphodiesterase (cGI-PDE, PDE3). Quazinone inhibits the phosphorylation of p42/p44 MAP kinase. Quazinone possesses antimitogenic effect .
    Quazinone
  • HY-13927
    Acetildenafil
    Inhibitor 99.0%
    Acetildenafil is a Sildenafil (HY-15025) analogue, a phosphodiesterase 5 (PDE5) inhibitor. Acetildenafil can be isolated from herbal products.
    Acetildenafil
  • HY-176296
    Vizenpistat
    Inhibitor
    Vizenpistat is an ENPP1 inhibitor that can be used in the study of cancer.
    Vizenpistat
  • HY-121381
    Kuraridine
    Inhibitor ≥98.0%
    Kuraridine is a prenylated flavonol extract from the roots of Sophora flavescens. Kuraridine has an inhibitory effect on cGMP specific phosphodiesterase type 5 (PDE5) (IC50=0.64 μM).
    Kuraridine
  • HY-108047
    MK-0873
    Inhibitor
    MK-0873 is a selective phosphodiesterase-4 (PDE4) inhibitor. MK-0873 increases intracellular levels of cyclic adenosine phosphate (cAMP) by inhibiting the activity of the PDE4 enzyme and subsequently activates protein kinase A (PKA). Activated PKA inhibits the activity of inflammatory cells and leads to direct relaxation of airway smooth muscle. MK-0873 can be used in studies of chronic obstructive pulmonary disease (COPD).
    MK-0873
  • HY-108045
    Lodenafil carbonate
    Inhibitor 98.0%
    Lodenafil carbonate, a dimer that acts as a proagent delivering Lodenafil in vivo, is an orally active phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile dysfunction (ED).
    Lodenafil carbonate
  • HY-11070
    MK-0952
    Inhibitor 99.71%
    MK-0952 is a selective and orally active PDE4 inhibitor, with an IC50 of 0.53 nM. MK-0952 has the potential for Alzheimer’s disease study.
    MK-0952
  • HY-125095
    Yonkenafil hydrochloride
    Inhibitor 99.43%
    Yonkenafil (Tunodafil) hydrochloride, a novel phosphodiesterase 5 (PDE5) inhibitor, is effective in reducing cerebral infarction, neurological deficits, edema, and neuronal damage in the infarcted area. Yonkenafil (Tunodafil) hydrochloride may improve cognitive function by modulating neurogenesis and has a potential therapeutic effect on Alzheimer's disease.
    Yonkenafil hydrochloride
  • HY-121162
    Mesembrine
    Inhibitor
    Mesembrine ((+)-Mesembrine) a main alkaloid that features an aryloctahydroindole skeleton. Mesembrine is a 5-HT transporter inhibitor with a Ki of 1.4 nM. Mesembrine also inhibits phosphodiesterase 4B (PDE4B) with an IC50 of 7.8 μM.
    Mesembrine
  • HY-100639R
    Roflumilast N-oxide (Standard)
    Inhibitor
    Roflumilast N-oxide (Standard) is the analytical standard of Roflumilast N-oxide. This product is intended for research and analytical applications. Roflumilast N-oxide is a PDE type 4 inhibitor.
    Roflumilast N-oxide (Standard)
  • HY-N2913
    Ayanin
    Inhibitor 98.18%
    Ayanin is a bioflavonoid isolated from Psychotria serpens. Ayanin is a non-selective phosphodiesterase1-4 inhibitor and can be used for the study of respiratory disease,such as allergic asthma et al.
    Ayanin
  • HY-N2284
    Sophoflavescenol
    Inhibitor 98.78%
    Sophoflavescenol is a prenylated flavonol, which shows great inhibitory activity with IC50 of 0.013 μM against Phosphodiesterase 5 (PDE5), and also inhibits RLAR, HRAR, AGE, BACE1, AChE and BChE with IC50s of 0.30 μM, 0.17 μM, 17.89 μg/mL, 10.98 μM, 8.37 μM and 8.21 μM, respectively.
    Sophoflavescenol
  • HY-152106A
    (+)-BAY-7081
    Inhibitor 99.21%
    (+)-BAY-7081 is an optical isomer of BAY-7081 (HY-152106). BAY-7081 is a potent, selective, orally active and soluble cyanopyridone-based PDE9A inhibitor with an IC50 of 15 nM.
    (+)-BAY-7081
  • HY-145063
    Enpp-1-IN-5
    Inhibitor 98.16%
    Enpp-1-IN-5 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). The ENPP 1 has broad specificity and can cleave a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds nucleotides and nucleotide sugars. Enpp-1-IN-5 has the potential for the research of cancer and infectious diseases (extracted from patent WO2019046778A1/WO2021203772A1, compound 1).
    Enpp-1-IN-5
  • HY-106844
    EMD 53998
    Inhibitor 99.59%
    EMD 53998 is a cardiotonic agent that increases myocardial contractility as an inhibitor for phosphodiesterase III (PDE III) and a calcium sensitizer. EMD 53998 increases myocardial contractility, reduces energy consumption and the risk of inducing arrhythmias.
    EMD 53998
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.